Compare PRAX & MUSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | MUSA |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.2B |
| IPO Year | 2020 | 2013 |
| Metric | PRAX | MUSA |
|---|---|---|
| Price | $299.14 | $478.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $572.13 | $445.00 |
| AVG Volume (30 Days) | 309.6K | ★ 315.8K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 24.10 |
| Revenue | N/A | ★ $21,529,400,000.00 |
| Revenue This Year | N/A | $17.24 |
| Revenue Next Year | $6,395.88 | $3.49 |
| P/E Ratio | ★ N/A | $19.24 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.70 | $345.23 |
| 52 Week High | $354.87 | $523.09 |
| Indicator | PRAX | MUSA |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 74.22 |
| Support Level | $290.36 | $386.86 |
| Resistance Level | $322.32 | N/A |
| Average True Range (ATR) | 16.93 | 18.16 |
| MACD | -3.50 | 6.05 |
| Stochastic Oscillator | 22.92 | 96.37 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Murphy USA Inc is mainly engaged in the marketing of retail motor fuel products and convenience merchandise through a network of several retail stores in the Southwest, Southeast, Midwest, and Northeast United States. The majority of Murphy USA's stores are located in proximity to Walmart Supercenters, but it also operates standalone stores that market gasoline and other products under the Murphy USA, Murphy Express, and QuickChek brands. In addition, the company also markets fuel to unbranded wholesale customers through a mixture of company-owned and third-party product distribution terminals and pipeline positions. The firm generates maximum revenue through retail sales of petroleum products, and the rest from merchandise sales and wholesale of petroleum products.